<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105311</url>
  </required_header>
  <id_info>
    <org_study_id>EC57-020-02-1</org_study_id>
    <nct_id>NCT02105311</nct_id>
  </id_info>
  <brief_title>Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure</brief_title>
  <official_title>A Prospective, Randomized Study Comparing the Effects of Selective Laser Trabeculoplasty and Travoprost on the Circadian Intraocular Pressure Variation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct this study to access the effect of selective laser trabeculoplasty&#xD;
      on 24-hour circadian tension curves of patients with open-angle glaucoma, normal tension&#xD;
      glaucoma and ocular hypertension. This treatment effect is compared with that of the&#xD;
      prostaglandin analogue, travoprost.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selective laser trabeculoplasty is an effective treatment for lowering intraocular pressure&#xD;
      in patients with open-angle glaucoma. Clinical evaluations of its effectiveness in individual&#xD;
      patients usually are derived from baseline and post-laser measurements of intraocular&#xD;
      pressure during office hours in the sitting position. Only a few studies have examined the&#xD;
      efficacy of laser trabeculoplasty beyond office hours. Although the 24-hour effect of laser&#xD;
      trabeculoplasty has been studied ,the study was conducted before the use of these new and&#xD;
      more potent intraocular pressure lowering drugs. So it doesn't have any study to determine&#xD;
      the effect of selective laser trabeculoplasty and travoprost to reduce the diurnal and&#xD;
      nocturnal variation of Iintraocular pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of circadian intraocular pressure</measure>
    <time_frame>Six weeks after recieving treatment</time_frame>
    <description>intraocular pressure values measured during daytime and nighttime, compare between selective laser trabeculoplasty and travoprost (include pre- and post-treatment intraocular pressure values)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Position related intraocular pressure</measure>
    <time_frame>Six weeks after the treatments</time_frame>
    <description>Intraocular pressure different when measuring in the sitting and supine position (include pre- and post-treatment intraocular pressure values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface disease</measure>
    <time_frame>Six weeks after the treatments</time_frame>
    <description>Using the glaucoma symptom scale-10 (GSS-10) and ocular surface disease questionnaire for evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Selective laser trabeculoplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treating with the selective laser trabeculoplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using eye drop: travoprost</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Selective laser trabeculoplasty</intervention_name>
    <description>Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)</description>
    <arm_group_label>Selective laser trabeculoplasty</arm_group_label>
    <other_name>The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost</intervention_name>
    <description>Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)</description>
    <arm_group_label>Travoprost</arm_group_label>
    <other_name>Travatan benzalkonium-free</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 year-old&#xD;
&#xD;
          -  Patients who were diagnosed as primary open-angle glaucoma, normal tension glaucoma,&#xD;
             and ocular hypertension either newly diagnosed or currently on medical therapy.&#xD;
&#xD;
          -  Agree to participate in the study, accept to be randomized to receive treatment, and&#xD;
             willing to sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Related to the severity of disease and visual acuity status&#xD;
&#xD;
          -  Advance glaucoma in the study eye&#xD;
&#xD;
          -  Have a very high intraocular pressure that need immediate treatment to prevent retinal&#xD;
             vein occlusion (intraocular pressure &gt;30 mmHg)&#xD;
&#xD;
          -  Currently on maximal tolerated medical treatment and unable to control intraocular&#xD;
             pressure&#xD;
&#xD;
          -  Currently on oral carbonic anhydrase inhibitor for intraocular pressure control&#xD;
&#xD;
          -  Single eye, the other eye blind from any cause&#xD;
&#xD;
        Related to surgical procedures&#xD;
&#xD;
          -  Prior laser trabeculoplasty&#xD;
&#xD;
          -  Prior glaucoma surgery&#xD;
&#xD;
          -  Prior retinal surgery&#xD;
&#xD;
          -  Underwent less than 3-month cataract extraction&#xD;
&#xD;
          -  Potential need for other ocular surgery within the 2-3-month follow-up period since&#xD;
             enrollment Related to underlying and ocular history&#xD;
&#xD;
          -  History of diabetic retinopathy staged as severe non-proliferative or worse&#xD;
&#xD;
          -  Narrow iridocorneal angle&#xD;
&#xD;
          -  Ocular condition precluding visualization of trabecular meshwork&#xD;
&#xD;
          -  Recently have ocular inflammation of any cause&#xD;
&#xD;
          -  Previous history of ocular trauma&#xD;
&#xD;
          -  Pregnant or breast-feeding women Related to the difficulty of having reliable&#xD;
             measurements&#xD;
&#xD;
          -  History of refractive surgery or any keratoplastic procedure&#xD;
&#xD;
          -  Corneal opacities or diseases making no suitable tonometry&#xD;
&#xD;
          -  Subjects with having poor or eccentric fixation or nystagmus&#xD;
&#xD;
          -  Excessive eye squeezing&#xD;
&#xD;
          -  Unable to lay down for measuring intraocular pressure in supine position during the&#xD;
             night time&#xD;
&#xD;
          -  Unable to have intraocular pressure checked every 2-hour such as have complicated&#xD;
             underlying diseases or having sleep deprivation Related to allergy&#xD;
&#xD;
          -  Known allergy to topical anesthesia&#xD;
&#xD;
          -  Known allergy to fluorescein solution&#xD;
&#xD;
          -  Known allergy to travoprost Related to compliance&#xD;
&#xD;
          -  Impairment preventing adequate understanding to sign an informed consent&#xD;
&#xD;
          -  Subject has demonstrated potential for non-compliance with the study protocol&#xD;
&#xD;
          -  Unwilling to be randomized to receive treatment&#xD;
&#xD;
          -  Unwilling to be washed out from currently treated drug(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weerawat Kiddee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Songkla University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Hatyai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Weerawat Kiddee</investigator_full_name>
    <investigator_title>Weerawat Kiddee</investigator_title>
  </responsible_party>
  <keyword>Intraocular pressure</keyword>
  <keyword>Selective laser trabeculoplasty</keyword>
  <keyword>Travoprost</keyword>
  <keyword>Ocular surface disease</keyword>
  <keyword>Glaucoma symptom scale</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzalkonium Compounds</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

